Table 1.
Baseline Characteristics*
| Characteristic | Placebo (n = 28) |
Etanercept (n = 28) |
P Value† |
|---|---|---|---|
| Age, y | 46.2 ± 8.3 | 45.1 ± 8.7 | .64 |
| WHR | 0.96 ± 0.07 | 0.96 ± 0.06 | .87 |
| BMI | 35.1 ± 4.8 | 37.9 ± 5.9 | .05 |
| Race | |||
| White | 19 | 18 | .24 |
| Black/African American | 9 | 8 | |
| Hispanic/Latino | 0 | 2 | |
| Sex | |||
| Male | 15 | 15 | >.99 |
| Female | 13 | 13 | |
| Fasting glucose, mg/dL | 98 ± 18 | 93 ± 13 | .31 |
| Fasting insulin, µIU/mL‡ | 17.0 ± 9.7 | 24.1 ± 25.3 | .21 |
| Fasting HDL-C, mg/dL | 40 ± 9 | 39 ± 9 | .66 |
| Systolic BP, mm Hg | 128 ± 15 | 131 ± 19 | .52 |
| Diastolic BP, mm Hg | 82 ± 10 | 82 ± 11 | .94 |
| Antihypertensive drug use | 18 | 13 | .18 |
| Statin use | 9 | 6 | .36 |
| C-reactive protein, mg/L | 5.1 ± 3.5 | 7.0 ± 3.9 | .07 |
| Adiponectin, µg/mL | 7.6 ± 3.6 | 7.0 ± 3.5 | .55 |
| Interleukin 6, ng/L | 4.5 ± 3.5 | 5.0 ± 4.3 | .68 |
| Fibrinogen, mg/dL | 443 ± 109 | 439 ± 108 | .91 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; WHR, waist-hip ratio.
SI conversion factors: To convert glucose to millimoles per liter, multiply by 0.0555; to convert insulin to picomoles per liter, multiply by 6.945; to convert HDL-C to millimoles per liter, multiply by 0.0259; to convert fibrinogen to micromoles per liter, multiply by 0.0294.
*
Data are presented as mean ± SD unless otherwise indicated.
†
P value for comparison at baseline by t test.
‡
Insulin reference range is less than 15 µIU/mL (<104 pmol/L).